Sanofi SA (SNYNF)
91.81
-2.69
(-2.85%)
USD |
OTCM |
Dec 16, 15:14
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 115.09B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 2.42% |
| Valuation | |
| PE Ratio | 23.26 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.167 |
| Price to Book Value | 1.477 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 4.049 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 34.79% |
Profile
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
| URL | https://www.sanofi.com |
| Investor Relations URL | https://www.sanofi.com/en/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | Oct. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 13, 2024 |
Ratings
Profile
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
| URL | https://www.sanofi.com |
| Investor Relations URL | https://www.sanofi.com/en/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | Oct. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 13, 2024 |